A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

NCT04077099 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

231

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: REGN5093

Sponsor

Regeneron Pharmaceuticals